Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.67 |
| ▸ | DPP4 | P27487 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.48 |
| ▸ | IDO1 | P14902 | 5/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | CFD | P00746 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20589595 | 0.98 | PNMT (0.64) | PNMTDPP4TAAR1IDO1MPO | |
| SCHEMBL3641106 | 0.85 | TAAR1 (0.64) | PNMTDPP4TAAR1MPO | |
| Hydrochloric Acid SCHEMBL3580072 | 0.83 | TAAR1 (0.62) | PNMTDPP4TAAR1IDO1CYP1A2 | |
| SCHEMBL4411424 | 0.81 | PNMT (0.43) | PNMTTAAR1IDO1MPOAKR1B1 | |
| SCHEMBL22854903 | 0.81 | PNMT (0.48) | PNMTDPP4TAAR1CFD | |
| SCHEMBL17552713 | 0.81 | PNMT (0.43) | PNMTTAAR1IDO1MPOAKR1B1 | |
| SCHEMBL3069271 | 0.81 | PNMT (0.43) | PNMTTAAR1IDO1MPOAKR1B1 | |
| SCHEMBL42705 | 0.80 | PNMT (1.00) | PNMTDPP4TAAR1IDO1 | |
| SCHEMBL22855023 | 0.79 | PNMT (0.52) | PNMTDPP4TAAR1IDO1 | |
| SCHEMBL8349402 | 0.79 | AKR1B1 (0.43) | PNMTTAAR1IDO1MPOAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 609 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3045206-B2 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE CO (US) | 2023-02-15 | — | — | EP | claimed |
| EP-2661433-B1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2017-08-16 | — | — | EP | claimed |
| US-8729089-B2 | Pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-05-20 | — | — | US | claimed |
| EP-2661433-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | Novartis AG (CH) | 2013-11-13 | — | — | EP | claimed |
| CN-103304438-A | N-substituted salicylamide type compound as well as preparation method and application thereof | UNIV SHANDONG | 2013-09-18 | — | — | CN | claimed |
| CN-102911124-A | Hydroxy-pyrimidone compound and preparation method and application thereof | UNIV SHANDONG | 2013-02-06 | — | — | CN | claimed |
| WO-2012093101-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2012-07-12 | — | — | WO | claimed |
| US-20080182870-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-31 | — | — | US | claimed |
| WO-2008077651-A1 | PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-03 | — | — | WO | claimed |
| US-12606541-B2 | PPARg modulators and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2026-04-02 | — | — | US | disclosed |
| US-12577241-B2 | Polycyclic pyridopyrazine derivative | SHIONOGI & CO., LTD. (JP) | 2026-03-17 | — | — | US | disclosed |
| US-12521388-B2 | Substituted dipyrido[1,2-a:1′,2′-d]pyrazines for treating viral infections | GILEAD SCIENCES, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-12485109-B2 | Pyrrolo 12.3-dipyrimidine compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20060258689-A1 | 2,3-Difluoro-benzyl)-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-amine, useful for the prevention and treatment of pain, inflammation, cognitive disorders, anxiety and depression in humans | EVOTEC SE (DE) | 2006-11-16 | — | — | US | disclosed |
| US-7125898-B2 | Nicotinamide derivatives useful as p38 inhibitors. | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-24 | — | — | US | disclosed |
| US-20050176964-A1 | Nicotinamide derivatives useful as p38 inhibitors | GLAXOSMITHKLINE LLC | 2005-08-11 | — | — | US | disclosed |
| CN-1633416-A | Nicotinamide derivatives as p38 inhibitors | SMITHKLINE BEECHAM CORP (US) | 2005-06-29 | — | — | CN | disclosed |
| US-6452056-B1 | REDUCING FLUORINATED BENZONITRILE TO A BENZYLAMINE WHICH IS REPLACED WITH A HYDROXYL GROUP | ASAHI GLASS COMPANY, LIMITED (JP) | 2002-09-17 | — | — | US | disclosed |
| EP-1114809-A1 | PROCESS FOR THE PREPARATION OF FLUOROBENZYL DERIVATIVES | Asahi Glass Co., Ltd. (JP) | 2001-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12485109-B2 | Pyrrolo 12.3-dipyrimidine compounds and analogues thereof | C5, DPYD, C9 | PNMT 1952/4885DPP4 51/4885TAAR1 4749/4885 |
| US-20060258689-A1 | 2,3-Difluoro-benzyl)-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-amine, useful for the prevention and treatment of pain, inflammation, cognitive disorders, anxiety and depression in humans | BDNF, OPRL1, GRIN2D | PNMT 164/4885DPP4 2125/4885TAAR1 250/4885 |
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | TFPI, F3, BTK | PNMT 2501/4885DPP4 844/4885TAAR1 1680/4885 |
| US-12577241-B2 | Polycyclic pyridopyrazine derivative | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CLIC1, CBR3 | PNMT 4671/4885DPP4 4658/4885TAAR1 723/4885 |
| US-12606541-B2 | PPARg modulators and methods of use | PPARG, PPARA, PPARD | PNMT 4606/4885DPP4 2198/4885TAAR1 786/4885 |
| US-20050176964-A1 | Nicotinamide derivatives useful as p38 inhibitors | MAPK1, MAPK7, MAPK6 | PNMT 3341/4885DPP4 3870/4885TAAR1 1772/4885 |
| US-20080182870-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | PNPO, DPYD, PNP | PNMT 823/4885DPP4 464/4885TAAR1 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.